Welcome to our dedicated page for ALLURION TECHNOLOGIES news (Ticker: ALUR), a resource for investors and traders seeking the latest updates and insights on ALLURION TECHNOLOGIES stock.
Allurion Technologies, Inc. develops a weight-loss platform centered on the Allurion Program, which combines the FDA PMA approved Allurion Gastric Balloon System featuring the Allurion Smart Capsule with a Virtual Care Suite that includes the Allurion Mobile App, Iris AI, Allurion Insights and the Allurion Connected Scale.
Company news centers on U.S. commercialization of the Allurion Smart Capsule, FDA regulatory status, provider training and commercial account onboarding, obesity-care partnerships and use of the program alongside GLP-1 therapies. Updates also cover preliminary operating results, balance-sheet and warrant-related capital actions, and listing-compliance matters involving Allurion common stock and warrants.
Allurion Technologies (NYSE: ALUR) announced a peer-reviewed, case-controlled study in 1,143 patients (BMI ≥30 kg/m2) showing the Allurion Smart Capsule plus individualized lifestyle intervention produced an average 20% weight reduction at 36 weeks with greater fat mass and visceral fat loss versus lifestyle intervention alone.
The study reports nearly twice the fat reduction and preserved muscle mass, and the company cites efficacy comparable to bariatric surgery and better real-world high-dose GLP-1 outcomes at a substantially lower cost. The Smart Capsule is swallowed in an outpatient visit, is filled in the stomach, and passes naturally after four months; combined with digital remote care for behavior change.
Allurion (NYSE: ALUR) announced a strategic distribution partnership with ProSurg Medical in Brazil on November 18, 2025 to expand access to its metabolically healthy weight loss program.
The agreement leverages ProSurg's 30 years of local experience and its network across over 300 hospitals to deploy the Allurion Program alongside multidisciplinary teams (dietitians, bariatric surgeons, endoscopic specialists) and to increase combined use with GLP-1 therapy to enhance short- and long-term outcomes.
Allurion (NYSE: ALUR) reported Q3 2025 results on November 12, 2025, with revenue of $2.7M and gross profit $1.3M (49% margin). The company said it passed FDA pre-approval inspection and BIMO audit with zero observations, entered PMA substantive review for the Allurion Smart Capsule and completed the Day-100 meeting. Allurion announced a transaction to exchange outstanding debt for convertible preferred equity and closed a $5M private placement. Q3 operating loss was $9.6M (adjusted loss $6.9M); cash was $6.1M as of September 30, 2025, excluding the private placement.
Allurion (NYSE: ALUR) reported major regulatory and financing developments on November 11, 2025. The company said it passed FDA pre-approval and BIMO inspections with zero findings and completed its Day-100 meeting, with the FDA not requesting additional human clinical data, signaling entry into the final stages of PMA review for the Allurion Smart Capsule.
Allurion also announced an exchange transaction to convert outstanding Revenue Interest Financing debt into Series B convertible preferred stock and a $5 million private placement (2,994,012 shares and warrants at $1.67 per share) to bolster working capital as it pursues FDA approval.
Allurion (NYSE: ALUR) will report third quarter 2025 financial results on Wednesday, November 12, 2025. Management will host a conference call and business update the same day at 8:30 AM ET.
To join by phone dial (888) 330-3417 (domestic) or +1 (646) 960-0804 (international) and use Conference ID 1905455. A live audio webcast will be available in the Events section of Allurion's Investor Relations website and a replay will be available by phone at (800) 770-2030 with Access Code 1905455. The archived webcast will also be posted on the Investor Relations site.
Allurion (NYSE: ALUR) published a multicenter, peer-reviewed retrospective study on October 7, 2025 reporting that two consecutive treatments with the Allurion Smart Capsule produced average 22.1% total body weight loss (19.3 kg) in 121 adults across 11 sites in six countries.
The study reported no serious device-related adverse events, aligns with the company’s FDA pivotal AUDACITY approach, and follows submission of the fourth and final PMA module to the FDA earlier in 2025.
Allurion Technologies (NYSE:ALUR), a company focused on metabolically healthy weight loss, has announced its participation in the upcoming ROTH 4th Annual Healthcare Opportunities Conference. The event will take place on October 9, 2025 at the Metropolitan Club in New York City. The company's management team will be available for one-on-one meetings with investors throughout the conference day.
Allurion Technologies (NYSE:ALUR) reported Q2 2025 financial results and announced a strategic pivot focusing on low-dose GLP-1 combination therapy. Revenue was $3.4 million, down from $11.8 million in Q2 2024, primarily due to distributor transitions. The company reported a reduced operating loss of $7.0 million, a 26% improvement year-over-year.
Key developments include a strategic partnership for manufacturing and R&D, including potential development of a GLP-1 drug-eluting balloon, and FDA acceptance of their Pre-Market Authorization application. The company ended Q2 with $12.7 million in cash and is implementing a restructuring plan expected to cost $1.5 million in Q3 2025.
The company also disclosed a potential financial restatement related to non-cash items concerning Revenue Interest Financing Agreement and convertible notes calculations.
Allurion Technologies (NYSE:ALUR), a company focused on metabolically healthy weight loss, has scheduled its second quarter 2025 financial results announcement for Wednesday, August 13, 2025.
Management will host a conference call and webcast at 8:30 AM ET to discuss the results and provide a business update. Investors can access the call via phone using the numbers (888) 330-3417 (domestic) or +1 (646) 960-0804 (international) with Conference ID 1905455. A webcast will be available in the Events section of Allurion's Investor Relations website.
Allurion Technologies (NYSE:ALUR) announced a strategic pivot focusing on low-dose GLP-1 combination therapy and muscle mass maintenance. The company has signed a term sheet with a strategic partner for expanding distribution and R&D, including potential development of a novel GLP-1 drug-eluting balloon.
Key developments include: submission of a protocol for a multi-center trial combining Allurion Program with low-dose GLP-1s, transition to distribution partners with GLP-1 prescription networks, and FDA acceptance of PMA application. Real-world data from 20,000 patients shows successful weight loss maintenance and muscle mass increases. Clinics piloting the combination approach grew 20% QoQ in Q2 2025.
Preliminary Q2 2025 results show $3 million revenue and $7 million operating loss, with operating expenses reduced by 50% YoY.